- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04611152
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLEAM)
September 29, 2023 updated by: Kodiak Sciences Inc
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with treatment-naïve DME.
The primary endpoint will be assessed at Year 1; additional secondary endpoints for efficacy will be assessed at Years 1 and 2.
Study Type
Interventional
Enrollment (Actual)
460
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79106
- Universitätsklinikum Freiburg
-
-
Bayern
-
Regensburg, Bayern, Germany, 93053
- Universitätsklinikum Regensburg
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Germany, 17036
- Dietrich Bonhoeffer Klinikum Neubrandenburg
-
-
Nordrhein-Westfalen
-
Köln, Nordrhein-Westfalen, Germany, 50935
- St. Elisabeth Krankenhaus
-
Münster, Nordrhein-Westfalen, Germany, 48145
- St Franziskus Hospital
-
-
-
-
-
Budapest, Hungary, 1214
- Jahn Ferenc Dél-pesti Kórház és Rendelőintézet
-
Pécs, Hungary, 7621
- Ganglion Medical Center
-
-
-
-
-
Roma, Italy, 00133
- Fondazione PTV Policlinico Tor Vergata
-
-
-
-
-
Jelgava, Latvia, LV-3001
- Signes Ozolinas Doctor Praxis in Ophthalmology
-
Riga, Latvia, LV-1002
- Pauls Stradins Clinical University Hospital
-
Riga, Latvia, LV-1006
- Riga Eastern Clinical University Hospital Clinic Bikernieki
-
Riga, Latvia, LV-1009
- Latvian American Eye Center
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research & Development Center LLC
-
-
-
-
-
Banská Bystrica, Slovakia, 974 01
- Fakultna nemocnica s poliklinikou F. D. Roosevelta
-
Bratislava, Slovakia, 826 06
- Univerzitna nemocnica Bratislava
-
Martin, Slovakia, 036 01
- Uvea Klinika, S.R.O.
-
Trebišov, Slovakia, 075 01
- Nemocnica s poliklinikou Trebisov a.s. Ocne oddelenie - jednonova zdravotna starostlivost
-
Trencín, Slovakia, 911 01
- Fakultna nemocnica Trencin
-
Žilina, Slovakia, 012 07
- Fakultna nemocnica s poliklinikou Zilina
-
-
-
-
-
Barcelona, Spain, 08028
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08025
- Hospital Dos de Maig
-
Barcelona, Spain, 08195
- Hospital Universitari General de Catalunya - Grupo Quironsalud
-
Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Valencia, Spain, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
Valladolid, Spain, 47012
- Hospital Universitario Río Hortega
-
Zaragoza, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
California
-
La Jolla, California, United States, 92037
- UCSD Jacobs Retina Center
-
Redlands, California, United States, 92374
- Retina Consultants of Southern California
-
Santa Maria, California, United States, 93454
- California Retina Consultants
-
Torrance, California, United States, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Lakewood, Colorado, United States, 80228
- Colorado Retina Associates PC
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Conneticut Eye Consultants
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- Retina Group of Florida
-
Clearwater, Florida, United States, 33761
- Blue Ocean Clinical Research
-
Gainesville, Florida, United States, 32607
- Vitreo Retinal Associates
-
Lakeland, Florida, United States, 33805
- Florida Retina Consultants
-
Melbourne, Florida, United States, 32901
- Florida Eye Associates
-
Orlando, Florida, United States, 32806
- Florida Retina Institute
-
Pensacola, Florida, United States, 32503
- Retina Specialty Institute
-
Tampa, Florida, United States, 33609
- Retina Associates of Florida
-
Tampa, Florida, United States, 33617
- Retina Vitreous Associates of Florida
-
Winter Haven, Florida, United States, 33880
- Center for Retina & Macular Disease
-
-
Illinois
-
Springfield, Illinois, United States, 62703
- Springfield Clinic LLP
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- Wolfe Eye Clinic
-
-
Kansas
-
Lenexa, Kansas, United States, 66215
- Retina Associates PA
-
Wichita, Kansas, United States, 67214
- Vitreo Retinal Consultants and Surgeons
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Retina Associates of Kentucky
-
-
Maryland
-
Hagerstown, Maryland, United States, 21740
- Cumberland Valley Retina Consultants PC
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49525
- Foundation for Vision Research
-
-
New Jersey
-
Bloomfield, New Jersey, United States, 07017
- The Retina Center of New Jersey
-
Teaneck, New Jersey, United States, 07605
- NJ Retina
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Charlotte Eye Ear Nose & Throat Associates, P.A.
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Retina Northwest
-
Springfield, Oregon, United States, 97477
- Cascade Medical Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- MidAtlantic Retina
-
-
South Carolina
-
Beaufort, South Carolina, United States, 29902
- Retina Research of Beaufort
-
Charleston, South Carolina, United States, 29414
- Charleston Neuroscience Institute - West Ashley
-
Florence, South Carolina, United States, 29501
- Pametto Retina Center
-
Ladson, South Carolina, United States, 29456
- Charleston Neuroscience Institute
-
West Columbia, South Carolina, United States, 29169
- Palmetto Retina Center
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Black Hills Regional Eye Institute
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Charles Retina Institute
-
Nashville, Tennessee, United States, 37203
- Tennessee Retina PC
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Southwest Retina Specialists
-
Arlington, Texas, United States, 76012
- Texas Retina Associates
-
Austin, Texas, United States, 78705
- Austin Retina Associates
-
Burleson, Texas, United States, 76028
- Star Retina
-
Houston, Texas, United States, 77030
- Retina Consultants of Texas
-
San Antonio, Texas, United States, 78240
- Retina Consultants of San Antonio
-
Willow Park, Texas, United States, 76087
- Strategic Clinical Research Group, LLC
-
-
Virginia
-
Lynchburg, Virginia, United States, 24502
- Piedmont Eye Center
-
-
Washington
-
Silverdale, Washington, United States, 98383
- Retina Center Northwest
-
Spokane, Washington, United States, 99204
- Spokane Eye
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent prior to participation in the study.
- Treatment-naïve diabetic macular edema, with vision loss and center involvement (if present) diagnosed within 9 months of screening.
- BCVA ETDRS letter score between 78 and 25 (-20/25 to 20/320 Snellen equivalent), inclusive, in the Study Eye.
- CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT instruments) as determined by the Reading Center.
- Decrease in vision determined by the Investigator to be primarily the result of DME.
- Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%.
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Macular edema in the Study Eye considered to be secondary to a cause other than DME.
- Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.
- High-risk proliferative diabetic retinopathy characteristics in the Study Eye.
- History of Pan-retinal Photocoagulation (PRP) laser in the Study Eye within 3 months of screening.
- Tractional retinal detachment in the Study Eye.
- Active retinal disease other than the condition under investigation in the Study Eye.
- Any history or evidence of a concurrent ocular condition present, that in the opinion of the Investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study (e.g., vitreomacular traction, epiretinal membrane).
- Active or suspected ocular or periocular infection or inflammation in either eye at Day 1.
- Any prior use of an approved or investigational treatment for DME in the Study Eye (e.g., anti-VEGF, intraocular or periocular steroids, macular laser photocoagulation).
- Women who are pregnant or lactating or intending to become pregnant during the study.
- Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value ≥100 mmHg while at rest.
- Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event.
- History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.
- Other protocol-specified exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KSI-301 (Arm A)
Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
|
Intravitreal Injection
The sham is a procedure that mimics an intravitreal injection.
It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye.
It will be administered to participants in both treatments arms at applicable visits to maintain masking.
|
Active Comparator: Aflibercept (Arm B)
Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
|
Intravitreal Injection
Other Names:
The sham is a procedure that mimics an intravitreal injection.
It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye.
It will be administered to participants in both treatments arms at applicable visits to maintain masking.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in BCVA to Assess Non-inferiority of KSI-301 to Aflibercept.
Time Frame: Day 1 to Year 1
|
Demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg with respect to mean change in best corrected visual acuity (BCVA).
|
Day 1 to Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in BCVA.
Time Frame: Day 1 to Year 2
|
Change in best corrected visual acuity (BCVA).
|
Day 1 to Year 2
|
Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in CST.
Time Frame: Day 1 to Year 2
|
Change in central subfield thickness (CST).
|
Day 1 to Year 2
|
Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in the diabetic retinopathy severity score (DRSS).
Time Frame: Day 1 to Year 2
|
Change in diabetic retinopathy severity score (DRSS).
|
Day 1 to Year 2
|
Durability of KSI-301 5 mg compared to aflibercept 2 mg measured by number of intravitreal injections during the study.
Time Frame: Day 1 to Year 2
|
Mean number of intravitreal injections during the course of the study.
|
Day 1 to Year 2
|
Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.
Time Frame: Day 1 to Year 2
|
Incidence of ocular and systemic adverse events.
|
Day 1 to Year 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pablo Velazquez-Martin, MD, Kodiak Sciences Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2020
Primary Completion (Actual)
May 11, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
October 19, 2020
First Submitted That Met QC Criteria
October 26, 2020
First Posted (Actual)
November 2, 2020
Study Record Updates
Last Update Posted (Actual)
October 2, 2023
Last Update Submitted That Met QC Criteria
September 29, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KS301P104
- 2020-001062-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms, Lung | Pulmonary DiseasesUnited States, France, Canada
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
-
Instituto de Olhos de GoianiaCompleted